|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, we present the case of a patient with recurrent metastatic melanoma who was found to have germline BAP1 and somatic BRAF mutation by clinical genomic sequencing.
|
29554022 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Our study provides evidence that high ALDH1A3 mRNA expression is not only a prognostic marker but also a predictive marker for BRAF/MEK inhibitor treatment response in BRAF-mutant metastatic melanoma patients.
|
31580832 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High concordance of BRAF mutational status in matched primary and metastatic melanoma.
|
30430609 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The MEK inhibitors cobimetinib and trametinib are used in combination with BRAF inhibitors to treat metastatic melanoma but increase rates of hemorrhage relative to BRAF inhibitors alone.
|
30252580 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Despite the clinical success of BRAF inhibitors like vemurafenib in treating metastatic melanoma, resistance has emerged through "paradoxical MEK/ERK signaling" where transactivation of one protomer occurs as a result of drug inhibition of the other partner in the activated dimer.
|
30977659 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In Japan, the immune checkpoint inhibitors ipilimumab, nivolumab and pembrolizumab, the BRAF inhibitor (BRAFi) vemurafenib, dabrafenib and MEK inhibitor (MEKi) trametinib have been available for the treatment of unresectable and metastatic melanoma.
|
29470725 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series.
|
30621779 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
All MM cases (excluding ocular MM, n = 837) diagnosed in three non-consecutive years marked by major changes in the first-line treatments (2012: interleukin-2 and BRAF inhibitors; 2014: anti-CTLA-4: Cytotoxic T-Lymphocyte Antigen 4 and 2016: anti-PD-1: programmed cell death protein 1 and MEK inhibitors) were retrieved.
|
30605822 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Accordingly, BRAF mutation determination is standard-of-care in metastatic melanoma, and a rapid, accurate assay is desirable.
|
31833840 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
|
30925943 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We evaluated whether BRAF and NRAS mutational testing could contribute to the diagnosis of dedifferentiated metastatic melanoma when immunostains are negative.
|
30315274 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dual inhibition of the mitogen-activated protein kinase pathway with BRAF/MEK inhibitor (BRAFi/MEKi) therapy is a standard treatment for BRAFV600-mutant metastatic melanoma and has historically been associated with grade III pyrexia or photosensitivity depending on the combination used.
|
31437754 |
2019 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We have developed and compared several metastatic melanoma (MM) models cultured as a monolayer (2D) and cocultured on three dimensional (3D) dermal equivalents with fibroblasts to better unravel factors modulating cell sensitivity to vemurafenib, a BRAF inhibitor.
|
30501565 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Data analysis from The Cancer Genome Atlas (TCGA) confirmed higher ZEB1-AS1 expression in metastatic melanoma and its association with hotspot mutations in BRAF (B-Raf proto-oncogene, serine/threonine kinase) gene and RAS family genes.
|
31383874 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conclusion This 5-year analysis represents the longest follow-up to date with BRAF + MEK inhibitor combination therapy in BRAF V600-mutant MM.
|
28991513 |
2018 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRAF inhibitor vemurafenib achieves high response rate and an improvement in survival in patients with BRAF-mutated metastatic melanoma.
|
29552321 |
2018 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Nicotinamide Phosphoribosyltransferase (NAMPT) as a Therapeutic Target in BRAF-Mutated Metastatic Melanoma.
|
29309612 |
2018 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that expressed somatic mutations in infrequently mutated genes beyond the well-characterized ones (e.g., <i>BRAF, RAS, CDKN2A, PTEN, TP53</i>), such as <i>RAC1</i> and <i>SPEN</i>, may have prognostic significance in MM.
|
30662871 |
2018 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We identified 2 patients with BRAF L597S metastatic melanoma who were treated with dMAPKi.
|
29903896 |
2018 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We provide a hypothetical example SMART design for BRAF wild-type metastatic melanoma as a framework for investigating immunotherapy treatment regimens.
|
28835379 |
2018 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Encorafenib/binimetinib for the treatment of BRAF-mutant advanced, unresectable, or metastatic melanoma: design, development, and potential place in therapy.
|
30588020 |
2018 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine whether the NLR before starting BRAF inhibitor (BRAFi) treatment in patients with (MM) is associated with progression-free survival (PFS).
|
29336315 |
2018 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
One hundred and eighty patients with BRAF-mutant metastatic melanoma who had progressed on treatment with single-agent BRAFi from February 2010 to April 2015 were included in a retrospective data analysis focused on patterns of progression, treatment beyond progression (TBP) and subsequent treatments after BRAFi therapy.
|
29266761 |
2018 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The outcomes of those with BM remain poor, particularly of those with BRAF mutant MM who fail TKI therapy with new BM.
|
29932306 |
2018 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations in the BRAF oncogene are observed in approximately 50% of cutaneous melanomas and the use of BRAF inhibitor (BRAFi) compounds has been reported to improve the outcome of patients with BRAF-mutated metastatic melanoma.
|
29956724 |
2018 |